What the company does
Kolon Life Science makes pharmaceutical ingredients and finished medicines, and also operates a supply-chain services business that handles logistics and distribution for other pharmaceutical companies.
Its products and services reach licensed drug manufacturers and healthcare providers. Listed on KOSDAQ, Korea's tech and small-cap exchange, the company runs three distinct divisions, pharmaceuticals, supply-chain services, and a biotechnology unit, with supply-chain services now accounting for the largest share of overall revenue.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue · FY2025
US$151.4M
▲ +29.5% YoY
Operating profit · FY2025
US$12.7M
Turned profitable
Net income · FY2025
US$18.1M
Turned profitable
Revenue
- FY2023US$90.3M
- FY2024US$116.9M
- FY2025US$151.4M
Operating profit
- FY2023−US$17.5M
- FY2024−US$16M
- FY2025US$12.7M
Net income
- FY2023−US$22.3M
- FY2024−US$67.5M
- FY2025US$18.1M
Key ratios (FY2025)
ROE
4.3%
Debt/Eq
56.6%
Op. margin
8.4%
Net margin
11.9%
Rev. YoY
▲ +29.5%
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?